Bone disease after kidney transplantation

Transplant International

Volumn 21, Issue 7, 2008, Pages 615-624

  Mitterbauer, Christa ^b   Oberbauer, Rainer ^a,b  

^a KH Elisabethinen ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone disease; Bone mineral density; Fractures; Kidney; Renal osteopathy; Transplantation

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; CLODRONIC ACID; CYCLOSPORIN; ERGOCALCIFEROL; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISOLONE; RISEDRONIC ACID; TACROLIMUS; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE DISEASE; CALCIUM INTAKE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIALYSIS; FRACTURE; HUMAN; HYPERPARATHYROIDISM; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; REVIEW;

BONE DISEASES, METABOLIC; FRACTURES, SPONTANEOUS; HUMANS; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 45449101178     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00665.x     Document Type: Review

References (64)

1. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003; 14: 617.
2. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333: 166.
3. Iwasaki Y, Yamato H, Nii-Kono T, et al. Insufficiency of PTH action on bone in uremia. Kidney Int Suppl 2006; 70: S34.
4. Kodras K, Haas M. Effect of kidney transplantation on bone. Eur J Clin Invest 2006; 36(Suppl. 2): 63.
5. Brandenburg VM, Ketteler M, Fassbender WJ, et al. Development of lumbar bone mineral density in the late course after kidney transplantation. Am J Kidney Dis 2002; 40: 1066.
6. Brandenburg VM, Politt D, Ketteler M, et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 2004; 77: 1566.
7. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996; 28: 105.
8. Grotz WH, Mundinger FA, Rasenack J, et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995; 10: 2096.
9. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994; 58: 912.
10. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999; 14: 456.
11. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999; 67: 1218.
12. Durieux S, Mercadal L, Orcel P, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002; 74: 496.
13. Schott AM, Hans D, Duboeuf F, et al. Quantitative ultrasound parameters as well as bone mineral density are better predictors of trochanteric than cervical hip fractures in elderly women. Results from the EPIDOS study. Bone 2005; 37: 858.
14. Grotz WH, Mundinger FA, Muller CB, et al. Trabecular bone architecture in female renal allograft recipients - assessed by computed tomography. Nephrol Dial Transplant 1997; 12: 564.
15. Mikuls TR, Julian BA, Bartolucci A, Saag KG. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75: 49.
16. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73.
17. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003; 15: 454.
18. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352.
19. Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997; 63: 380.
20. Nowacka-Cieciura E, Durlik M, Cieciura T, et al. Positive effect of steroid withdrawal on bone mineral density in renal allograft recipients. Transplant Proc 2001; 33: 1273.
21. van den Ham EC, Kooman JP, Christiaans ML, van Hooff JP. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int 2003; 16: 82.
22. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 1995; 9: 20.
23. Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571.
24. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989; 124: 2179.
25. Orcel P, Denne MA, de Vernejoul MC. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 1991; 128: 1638.
26. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996; 11: 1.
27. Monegal A, Navasa M, Guanabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68: 83.
28. Goffin E, Devogelaer JP, Lalaoui A, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002; 15: 73.
29. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 1992; 19: 99.
30. Torres A, Rodriguez AP, Concepcion MT, et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13(Suppl. 3): 94.
31. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000; 14: 342.
32. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000; 11: 1141.
33. Reinhardt W, Bartelworth H, Jockenhovel F, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998; 13: 436.
34. Torres A, Machado M, Concepcion MT, et al. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 1996; 50: 1726.
35. Torregrosa JV, Campistol JM, Montesinos M, Pons F, Martinez de Osaba MJ. Evolution of bone mineral density after renal transplantation: related factors. Nephrol Dial Transplant 1995; 10(Suppl. 6): 111.
36. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17: 268.
37. Carlini RG, Rojas E, Weisinger JR, et al. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000; 36: 160.
38. Cueto-Manzano AM, Konel S, Hutchison AJ, et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int 1999; 55: 2021.
39. Casez JP, Lippuner K, Horber FF, Montandon A, Jaeger P. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002; 17: 1318.
40. Cueto-Manzano AM, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ. Association of sex hormone status with the bone loss of renal transplant patients. Nephrol Dial Transplant 2001; 16: 1245.
41. Brandenburg VM, Ketteler M, Heussen N, et al. Lumbar bone mineral density in very long-term renal transplant recipients: impact of circulating sex hormones. Osteoporos Int 2005; 16: 1611.
42. Kwan JT, Almond MK, Evans K, Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab 1992; 18: 166.
43. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1.
44. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006; 36(Suppl. 2): 13.
45. Borchhardt K, Sulzbacher I, Benesch T, Fodinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007; 7: 2515.
46. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.8. Bone disease. Nephrol Dial Transplant 2002; 17(Suppl. 4): 43.
47. Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Effects of bisphosphonates on bone loss in the first year after renal transplantation - a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21: 2275.
48. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669.
49. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530.
50. Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int 2000; 57: 684.
51. Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63: 1130.
52. Kovac D, Lindic J, Kandus A, Bren AF. Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation 2000; 70: 1542.
53. Torregrosa JV, Fuster D, Pedroso S, et al. Weekly risedronate in kidney transplant patients with osteopenia. Transpl Int 2007; 20: 708.
54. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007; 3: CD005015.
55. Sansoni P, Passeri G, Fagnoni F, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995; 10: 1719.
56. Fryer J, Grant D, Jiang J, et al. Influence of macrophage depletion on bacterial translocation and rejection in small bowel transplantation. Transplantation 1996; 62: 553.
57. Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 2002; 34: 2111.
58. Nam JH, Moon JI, Chung SS, et al. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc 2000; 32: 1876.
59. Grotz WH, Rump LC, Niessen A, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998; 66: 1004.
60. El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 2005; 67: 2039.
61. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434.
62. Cejka D, Kodras K, Benesch T, et al. Effekte von rekombinantem Parathormon auf den Knochenverlust nach Nierentransplantation. Journal für Mineralstoffwechsel 2007; 14(abstract): 175.
63. Bergua C, Torregrosa JV, Cofan F, Oppenheimer F. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 2007; 39: 2254.
64. Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 323.